oasis 1 semaglutide Oral 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial In the OASIS 4 phase
Description
Headaches during early semaglutide treatment reflect the body's adjustment to medication rather than treatment failure

Engineering semaglutide: three modifications to native GLP-1 (2015) The synthesis and structure-activity characterization of semaglutide were reported by Lau, Bloch, Schffer, and colleagues at Novo Nordisk in the Journal of Medicinal Chemistry in 2015 [7]
These may represent individual susceptibility, coincidental timing, or the general effects of significant physiological change during rapid weight loss

Interplay between exercise and gut microbiome in the context of human health and performance